A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs in Patients Undergoing an Elective Abdominal Liposuction Procedure.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs in Patients Undergoing an Elective Abdominal Liposuction Procedure.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Sufentanil/triazolam (Primary)
  • Indications Anxiety; Procedural pain
  • Focus Therapeutic Use
  • Sponsors AcelRx Pharmaceuticals
  • Most Recent Events

    • 18 May 2011 Results presented at the 30th Annual Scientific Meeting of the American Pain Society, according to a AcelRx Pharmaceuticals media release.
    • 28 Oct 2009 Results reported in an AcelRx media release.
    • 08 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top